Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback